106 related articles for article (PubMed ID: 628025)
1. Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication.
Eagan RT; Ingle JN; Rubin J; Frytak S; Moertel CG
J Natl Cancer Inst; 1978 Jan; 60(1):93-6. PubMed ID: 628025
[TBL] [Abstract][Full Text] [Related]
2. Maytansine: a phase I study of an ansa macrolide with antitumor activity.
Blum RH; Kahlert T
Cancer Treat Rep; 1978 Mar; 62(3):435-8. PubMed ID: 348312
[TBL] [Abstract][Full Text] [Related]
3. A therapeutic trial of maytansine.
Blum RH; Wittenberg BK; Canellos GP; Mayer RJ; Skarin AT; Henderson IC; Parker LM; Frei E
Cancer Clin Trials; 1978; 1(2):113-7. PubMed ID: 757139
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial.
Ravry MJ; Omura GA; Birch R
Am J Clin Oncol; 1985 Apr; 8(2):148-50. PubMed ID: 3834790
[TBL] [Abstract][Full Text] [Related]
5. Initial clinical trials of maytansine, an antitumor plant alkaloid.
Chabner BA; Levine AS; Johnson BL; Young RC
Cancer Treat Rep; 1978 Mar; 62(3):429-33. PubMed ID: 348311
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study.
Thigpen JT; Ehrlich CE; Creasman WT; Curry S; Blessing JA
Am J Clin Oncol; 1983 Jun; 6(3):273-5. PubMed ID: 6846245
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of maytansine using a 3-day schedule.
Cabanillas F; Rodriguez V; Hall SW; Burgess MA; Bodey GP; Freireich EJ
Cancer Treat Rep; 1978 Mar; 62(3):425-8. PubMed ID: 348310
[TBL] [Abstract][Full Text] [Related]
8. A phase I-II study of maytansine utilizing a weekly schedule.
Franklin R; Samson MK; Fraile RJ; Abu-Zahra H; O'Bryan R; Baker LH
Cancer; 1980 Sep; 46(5):1104-8. PubMed ID: 7214295
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of weekly maytansine given by iv bolus or 24-hour infusion.
Chahinian AP; Nogeire C; Ohnuma T; Greenberg ML; Sivak M; Jaffrey IS; Holland JF
Cancer Treat Rep; 1979; 63(11-12):1953-60. PubMed ID: 526928
[No Abstract] [Full Text] [Related]
10. Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Thigpen JT; Ehrlich CE; Conroy J; Blessing JA
Am J Clin Oncol; 1983 Aug; 6(4):427-30. PubMed ID: 6869315
[TBL] [Abstract][Full Text] [Related]
11. Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study.
Neidhart JA; Laufman LR; Vaughn C; McCracken JD
Cancer Treat Rep; 1980; 64(4-5):675-7. PubMed ID: 7427953
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion.
Kuhn JG; Von Hoff DD; Hersh M; Melink T; Clark GM; Weiss GR; Coltman CA
Eur J Cancer Clin Oncol; 1989 May; 25(5):797-803. PubMed ID: 2737217
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule.
Moriconi WJ; Taylor S; Slavik M; Belt RJ; Haas CD; Hoogstraten B
Invest New Drugs; 1985; 3(1):57-62. PubMed ID: 3157661
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
Valdivieso M; Bedikian AY; Burgess MA; Savaraj N; Jeffers WB; Bodey GP
Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Dy GK; Thomas JP; Wilding G; Bruzek L; Mandrekar S; Erlichman C; Alberti D; Binger K; Pitot HC; Alberts SR; Hanson LJ; Marnocha R; Tutsch K; Kaufmann SH; Adjei AA
Clin Cancer Res; 2005 May; 11(9):3410-6. PubMed ID: 15867242
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of maytansine in patients with advanced head and neck cancer.
Creagan ET; Fleming TR; Edmonson JH; Ingle JN
Cancer Treat Rep; 1979; 63(11-12):2061-2. PubMed ID: 526939
[No Abstract] [Full Text] [Related]
19. Phase I study of ICRF-187 using a daily for 3 days schedule.
Von Hoff DD; Howser D; Lewis BJ; Holcenberg J; Weiss RB; Young RC
Cancer Treat Rep; 1981; 65(3-4):249-52. PubMed ID: 6786738
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
Brown TD; Ettinger DS; Donehower RC
J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
